Jason Bednar
Stock Analyst at Piper Sandler
(2.13)
# 2,894
Out of 5,072 analysts
189
Total ratings
38.19%
Success rate
-5.25%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Neutral | $200 → $190 | $195.49 | -2.81% | 11 | Nov 7, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $151.90 | +13.23% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $85.77 | +14.26% | 8 | Nov 7, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $17.37 | -2.13% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $87.60 | +24.43% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $147.50 | +35.59% | 32 | Oct 30, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $78.21 | +6.12% | 14 | Aug 28, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $146.49 | +43.35% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $21.05 | -9.74% | 13 | Aug 1, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.70 | +47.06% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $12.64 | +168.99% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $5.25 | -33.33% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.09 | +44.27% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $75.50 | +1.99% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.41 | +86.72% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $267.79 | -1.04% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.58 | +67.60% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.90 | +79.49% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $1.34 | +1,392.54% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $578.87 | -35.74% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $79.96 | +18.81% | 1 | Apr 19, 2023 |
Becton, Dickinson and Company
Nov 7, 2025
Maintains: Neutral
Price Target: $200 → $190
Current: $195.49
Upside: -2.81%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $151.90
Upside: +13.23%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $85.77
Upside: +14.26%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $17.37
Upside: -2.13%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $87.60
Upside: +24.43%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $147.50
Upside: +35.59%
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $78.21
Upside: +6.12%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $146.49
Upside: +43.35%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $21.05
Upside: -9.74%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.70
Upside: +47.06%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.64
Upside: +168.99%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $5.25
Upside: -33.33%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.09
Upside: +44.27%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $75.50
Upside: +1.99%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.41
Upside: +86.72%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $267.79
Upside: -1.04%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.58
Upside: +67.60%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.90
Upside: +79.49%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $1.34
Upside: +1,392.54%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $578.87
Upside: -35.74%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $79.96
Upside: +18.81%